PMID- 15621108
OWN - NLM
STAT- MEDLINE
DCOM- 20050705
LR  - 20181201
IS  - 0041-1345 (Print)
IS  - 0041-1345 (Linking)
VI  - 36
IP  - 9
DP  - 2004 Nov
TI  - Third dose of basiliximab in pediatric renal transplantation.
PG  - 2628-31
AB  - Antibody induction therapy is frequently used in pediatric renal transplantation 
      to reduce risk of early rejection. We previously reported lower rates of human 
      herpes virus type 6 (HHV-6) reactivation in patients receiving monoclonal 
      antibody induction with basiliximab, compared to patients receiving antithymocyte 
      globulin/antilymphocyte globulin treatment. Subclinical rejection events were 
      still present in many patients in the first 6 months after transplantation. This 
      prompted a third dose of basiliximab to be administered at day 21 in addition to 
      the standard two doses given immediately prior to transplantation and on day 4. 
      No significant reduction of subclinical rejections was noted in the 11 patients 
      receiving triple dosing of basiliximab. Two patients developed an allergic 
      reaction responsive to intravenous fluids, steroids, and antihistamines with full 
      resolution within 30 minutes of administration. There was no increase in de novo 
      infection or reactivation of HHV-6 or Epstein-Barr virus in this group compared 
      to patients receiving two doses of basiliximab. The goal of reduction of early 
      subclinical rejection events was not achieved with the third dosing of 
      basiliximab in this initial group of pediatric renal transplant patients. 
      However, 63.6% of patients receiving triple basiliximab remained free of clinical 
      and/or subclinical rejection for the first 6 months posttransplant compared to 
      only 36.4% remaining rejection-free for the same interval in the group who 
      received the conventional two doses of basiliximab.
FAU - Acott, P D
AU  - Acott PD
AD  - Dalhousie University, Halifax, Nova Scotia B3K 6R8, Canada.
FAU - Lawen, J G
AU  - Lawen JG
FAU - Crocker, J F S
AU  - Crocker JF
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Controlled Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 9927MT646M (Basiliximab)
SB  - IM
MH  - Antibodies, Monoclonal/administration & dosage/*therapeutic use
MH  - Antilymphocyte Serum/administration & dosage/therapeutic use
MH  - Basiliximab
MH  - Child
MH  - Disease-Free Survival
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/*therapeutic use
MH  - Intraoperative Period
MH  - Male
MH  - Postoperative Period
MH  - Recombinant Fusion Proteins/administration & dosage/*therapeutic use
MH  - Retrospective Studies
EDAT- 2004/12/29 09:00
MHDA- 2005/07/06 09:00
CRDT- 2004/12/29 09:00
PHST- 2004/12/29 09:00 [pubmed]
PHST- 2005/07/06 09:00 [medline]
PHST- 2004/12/29 09:00 [entrez]
AID - S0041-1345(04)01153-4 [pii]
AID - 10.1016/j.transproceed.2004.09.081 [doi]
PST - ppublish
SO  - Transplant Proc. 2004 Nov;36(9):2628-31. doi: 10.1016/j.transproceed.2004.09.081.